Ghrelin and LEAP2 affect insulin and glucagon secretion in mouse but not in human islets, and their effects in mouse islets are mediated by somatostatin

Murdasov, Yevhenii;Gilon, Patrick
(2024) 60th EASD Annual Meeting of the European Association for the Study of Diabetes — Location: (Spain) Madrid (9.September.2024)

Files

2024_Murdasov_EASD_Abstract_421.pdf
  • Open Access
  • Adobe PDF
  • 194.89 KB
Download

Details

Authors
Abstract
BACKGROUND AND AIMS : Ghrelin, which activates the growth hormone secretagogue receptor 1a (GHS-R1a), stimulates appetite (“hunger hormone”) and impairs glucose homeostasis. Conversely, liver-expressed antimicrobial peptide-2 (LEAP2), which acts as an endogenous antagonist and inverse agonist of GHS-R1a, counteracts the effects of ghrelin and improves glucose homeostasis. The mechanisms of control of insulin (INS) and glucagon (GCG) secretion by ghrelin and LEAP2 are debated or poorly understood. Since δ-cells strongly express GHS-R1a, ghrelin and LEAP2 are expected to affect somatostatin (SST) secretion. [...]
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Murdasov, Y., & Gilon, P. (2024). Ghrelin and LEAP2 affect insulin and glucagon secretion in mouse but not in human islets, and their effects in mouse islets are mediated by somatostatin. Diabetologia : clinical and experimental diabetes and metabolism, 67(Suppl 1), S211-S212. https://hdl.handle.net/2078.5/249061 (Original work published 2024)